Question 1

What is Anoro Ellipta?

Accepted Answer

Anoro Ellipta is a combination therapy that includes an anticholinergic and a long-acting beta2-adrenergic agonist. These two classes of medicine work together to relax the muscles in the airways.

By targeting these muscles, the medication helps to keep the air passages open and improve overall airflow. It is designed to provide consistent, long-term support for lung function.

Question 2

What is Anoro Ellipta used for?

Accepted Answer

Anoro Ellipta is used to treat chronic obstructive pulmonary disease .

Question 3

How does Anoro Ellipta work?

Accepted Answer

Mechanism of Action

Anoro Ellipta is a combination inhaler that uses two different types of bronchodilators to treat COPD. These medications work in different ways to keep the muscles in the lungs relaxed and the airways open.

Umeclidinium

Umeclidinium is a long-acting muscarinic antagonist (LAMA), also known as an anticholinergic. It works by blocking the action of a chemical called acetylcholine on the muscarinic receptors in the lungs. When acetylcholine is blocked, it prevents the muscles surrounding the airways from tightening or narrowing.

Vilanterol

Vilanterol is a long-acting beta2-adrenergic agonist (LABA). It works by stimulating specific receptors called beta2-receptors located on the smooth muscle cells of the airways. This stimulation causes the muscles to relax, which widens the airways and allows more air to flow in and out of the lungs.

Combined Effect

By using two different pathways to relax the airway muscles, Anoro Ellipta provides a more significant opening of the airways than either medication used alone. Because both ingredients are long-acting, the effects typically last for 24 hours, which is why the medication is used once daily for maintenance treatment.

It is important to note that Anoro Ellipta is designed for long-term maintenance and does not work quickly enough to treat a sudden asthma attack or a sudden worsening of COPD symptoms.

Question 4

What are the active ingredients in Anoro Ellipta?

Accepted Answer

The active ingredients in Anoro Ellipta are Umeclidinium and Vilanterol .

Question 5

What are the side effects of Anoro Ellipta?

Accepted Answer

Common side effects of Anoro Ellipta may include:

sore throat

sinusitis

constipation

and others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Anoro Ellipta?

Accepted Answer

Anoro Ellipta belongs to the LAMA and LABA combination drug class.

Question 7

What is the dosage of Anoro Ellipta and how do I take it?

Accepted Answer

How to Use

This medication is for oral inhalation only. It should be used once every 24 hours at the same time each day. It is important to use the medication regularly to maintain its effectiveness, even if you do not feel symptoms. This inhaler is intended for long-term maintenance and should not be used to treat sudden breathing problems.

Administration Steps

Slide the cover of the inhaler down until you hear a click. This action prepares the dose.

Breathe out fully, away from the inhaler. Do not breathe out into the mouthpiece.

Place the mouthpiece between your lips and close them firmly around it.

Take one long, steady, deep breath in through your mouth. Do not breathe in through your nose.

Remove the inhaler from your mouth and hold your breath for several seconds, or as long as is comfortable.

Breathe out slowly and gently.

Close the inhaler by sliding the cover back up over the mouthpiece.

Do not wash the mouthpiece or any part of the inhaler. Keep the inhaler dry and store it with the cover closed until you are ready for your next dose.

Missed Dose

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular timing. Do not use more than the prescribed amount in a 24-hour period.

Question 8

Is Anoro Ellipta safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There are no adequate and well-controlled studies of Anoro Ellipta in pregnant women to determine if it poses a risk to human pregnancy. Animal studies have shown some adverse effects on the fetus, but only when the medication was administered at doses significantly higher than those used by humans. Because of the lack of human data, this medication should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the unborn baby.

Labor and Delivery

Anoro Ellipta contains vilanterol, a long-acting beta2-agonist. This class of medication can potentially interfere with uterine contractions. Therefore, the use of this medication during labor and delivery should be limited to situations where the clinical benefit is clear.

Breastfeeding

It is currently unknown whether the active ingredients in Anoro Ellipta, umeclidinium and vilanterol, pass into human breast milk. Many medications are excreted in human milk, and there is a potential for serious adverse reactions in nursing infants. Patients should consult with a healthcare provider to decide whether to discontinue breastfeeding or discontinue the medication, taking into account the importance of the drug to the mother's health.

Question 9

What forms and strengths does Anoro Ellipta come in?

Accepted Answer

Available Forms

Anoro Ellipta is supplied as a dry powder for oral inhalation. The medication is contained within a plastic inhaler device that holds two separate foil blister strips. Each time the inhaler is activated, a dose of the powder is prepared for inhalation.

Inhalation Powder: A dry powder formulation intended for oral inhalation only.

Ellipta Inhaler: A disposable inhaler device designed to deliver the medication directly to the lungs.

Question 10

What is the FDA approval status of Anoro Ellipta?

Accepted Answer

FDA Approval History

Anoro Ellipta was approved by the U.S. Food and Drug Administration (FDA) in December 2013. It was the first once-daily product approved in the United States that combines two long-acting bronchodilators—an anticholinergic and a long-acting beta2-adrenergic agonist (LABA)—in a single inhaler.

Approved Indications

This medication is FDA-approved for the long-term, once-daily maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD). This indication includes patients with:

Chronic bronchitis

Emphysema

Regulatory Limitations

The FDA has established specific limitations regarding the use of Anoro Ellipta:

Not for Acute Symptoms: It is not indicated for the relief of acute bronchospasm. Patients must use a separate rescue inhaler for sudden breathing problems.

Not for Asthma: Anoro Ellipta is not approved for the treatment of asthma. Its safety and effectiveness for asthma patients have not been established.

Pediatric Use: This medication is not approved for use in children, as its safety and efficacy in pediatric populations have not been studied.

There are currently no Risk Evaluation and Mitigation Strategies (REMS) or active safety recalls associated with Anoro Ellipta according to official regulatory records.

Question 11

What should I know about Anoro Ellipta and cost?

Accepted Answer

Insurance and Coverage

The out-of-pocket cost for Anoro Ellipta is primarily determined by your health insurance plan. Most Medicare Part D and private insurance plans provide coverage for this medication, though it may be placed on a specific tier that requires a copayment or coinsurance. It is recommended to check your plan's formulary to determine your specific coverage level.

Generic Availability

Anoro Ellipta is a brand-name medication containing umeclidinium and vilanterol. Currently, there is no FDA-approved generic equivalent available in the United States. Because generic drugs typically cost less than brand-name products, the lack of a generic option may contribute to higher costs for patients without insurance.

Financial Assistance

For individuals who have difficulty affording the medication, the manufacturer may offer savings cards or patient assistance programs. These programs are generally designed for eligible patients who are uninsured or have commercial insurance. Eligibility often depends on income requirements and the type of insurance coverage you have.

Anoro Ellipta

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?